enGene Therapeutics (ENGN) Cash & Equivalents (2022 - 2026)

enGene Therapeutics (ENGN) has reported Cash & Equivalents for 5 consecutive years, with $29.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents fell 48.17% year-over-year to $29.8 million; the TTM figure through Apr 2026 stood at $29.8 million (down 48.17% YoY), while the FY2025 annual figure was $50.2 million, down 71.01% from the prior year.
• Cash & Equivalents retreated to $29.8 million in Q2 2026 per ENGN's latest filing, from $36.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $264.8 million in Q2 2024 and bottomed at $20.4 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $96.0 million across 5 years, with a median of $59.9 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 298.95% — and 2025, when it slumped 87.34%.
• enGene Therapeutics' Cash & Equivalents stood at $20.4 million in 2022, then soared by 298.95% to $81.5 million in 2023, then soared by 112.22% to $173.0 million in 2024, then slumped by 71.01% to $50.2 million in 2025, then plunged by 40.53% to $29.8 million in 2026.
• Business Quant data shows ENGN's Cash & Equivalents at $29.8 million in Q2 2026, $36.6 million in Q1 2026, and $50.2 million in Q4 2025.